occur

Latest Survey from Sotera Digital Reveals Shocking State of Mobile Phone Security in the Workplace.

Source Node:
Time Stamp: February 5, 2024 8:19 AM - Modified On: February 5, 2024 - Published By:
Source Cluster:
Republished By Plato

February 5, 2024, New York - Sotera Digital Security, a leading US based provider of secure communications solutions, has today released its findings from a survey it conducted among over 1,000 senior personnel of large businesses and multinational corporations across the globe. Sectors covered by the survey participants focused on those that require the need for ultra-secure and private communications - both regionally and worldwide - with clients, colleagues and suppliers; namely legal, pharmaceutical, media and corporate affairs, government, and blockchain / AI tech specialists. The survey results provide key

Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research

Source Node:
Time Stamp: August 29, 2023 8:20 AM - Modified On: August 29, 2023 - Published By:
Source Cluster:
Republished By Plato

Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies, has made significant strides in the fight against Parkinson's disease (PD). The Company's lead drug candidate, GT-02287, has demonstrated extraordinary potential in mitigating the effects of Parkinson's disease across two distinct preclinical models of the ailment. These findings suggest that GT-02287 has the capacity to alleviate Parkinson's disease pathology and enhance motor function. A notable highlight is the substantial reduction of plasma Neurofilament Light Chain (NfL) levels, an emerging biomarker for neurodegeneration. This advancement

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Source Node:
Time Stamp: June 7, 2023 12:22 PM - Modified On: June 7, 2023 - Published By:
Source Cluster:
Republished By Plato

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating